Refining sorafenib therapy: Lessons from clinical practice

Calogero Camma', Antonio Craxi, Massimo Colombo, Giovan Giuseppe Di Costanzo, Luigi Bolondi, Bruno Daniele, Federico Spandonaro, Stefano Fagiuoli, Paolo Bruzzi, Franco Trevisani, Corrado Boni, Romano Danesi, Armando Santoro

Risultato della ricerca: Articlepeer review

15 Citazioni (Scopus)

Abstract

Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symptomatic progression should also be considered. If second-line therapies or trials are unavailable, continuing sorafenib beyond radiologic progression may provide a clinical benefit. Our recommendations enable the maximization of treatment duration, and hence clinical benefit, for patients.
Lingua originaleEnglish
pagine (da-a)449-465
Numero di pagine17
RivistaFuture Oncology
Volume11
Stato di pubblicazionePublished - 2015

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2730???
  • ???subjectarea.asjc.1300.1306???

Fingerprint

Entra nei temi di ricerca di 'Refining sorafenib therapy: Lessons from clinical practice'. Insieme formano una fingerprint unica.

Cita questo